Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit

Abstract

Informed choice approaches lead to high rates of unsystematic PSA testing, especially among those least likely to benefit and most likely to be harmed, argue <b>Andrew Vickers and colleagues</b>